Clinical Research Papers:

The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis

Wei Liu, Jian-Guo Zhou, Yi Sun, Lei Zhang and Bao-Cai Xing _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:37277-37287. https://doi.org/10.18632/oncotarget.8671

Metrics: PDF 2452 views  |   HTML 2497 views  |   ?  


Wei Liu1,*, Jian-Guo Zhou2,*, Yi Sun1, Lei Zhang1 and Bao-Cai Xing1

1 Hepatopancreatobiliary Surgery Department I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing , PR China

2 Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi Medical University, Zunyi, China

* These authors have contributed equally to this work

Correspondence to:

Bao-Cai Xing, email:

Keywords: neoadjuvant, chemotherapy, colorectal liver metastases, meta-analysis

Received: November 25, 2015 Accepted: March 28, 2016 Published: April 09, 2016


Neoadjuvant chemotherapy is being increasingly accepted as an effective treatment of resectable colorectal liver metastases (CRLM), but it may also damage the hepatic parenchyma. We performed a meta-analysis to compare the outcomes of patients who received neoadjuvant chemotherapy (NEO) prior to hepatic resection with hepatic resection without neoadjuvant chemotherapy (SG). Eligible trials were identified from Embase, PubMed, the Web of Science and the Cochrane library. Hazard ratios (HRs) with a 95% confidence intervals (CIs) were used to measure the pooled effect using a random-effects model. Statistical heterogeneity was detected by I2 test. Sensitivity analyses and publication bias were also assessed. The study outcomes included 3-year, 5-year disease-free and overall survival rate, respectively. Eighteen studies involving 6,254 patients were included. The pooled HRs for 5-year DFS and 5-year OS for NEO in the included studies calculated using the random-effects model were 1.38 (95 % CI; 1.26-1.51, p=0.00; I2=9.6%, p=0.36) and 1.19 (95% CI: 1.02-1.38; p=0.03; I2=49.2%, p=0.03), respectively. For CRLM patients with factors indicating a high risk of recurrence, the pooled HR for 5-year OS of NEO in the included studies calculated using the random-effects model was 0.69 (95% CI: 0.55-0.87; p=0.00; I2=0.0%, p=0.48). These results suggest neoadjuvant chemotherapy improved survival of patients with initially resectable CRLM and a high risk of disease recurrence.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8671